Determination of true ERBB2 Gene amplification in breast cancer by quantitative PCR using a reference and a novel control gene

Applied Immunohistochemistry and Molecular Morphology

Volumn 24, Issue 3, 2016, Pages 179-187

  Chamizo, Cristina ^a   Rojo, Federico ^a   Madoz Gúrpide, Juan ^a  

^a UAM)   (Spain)

Author keywords

breast cancer; ERBB2 HER2 amplification; predictive marker; quantitative real Time PCR

Indexed keywords

ALGORITHM; ARTICLE; BREAST CANCER; CENTROMERE; CHROMOSOME 17; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE PCR ALGORITHM; RPP30 GENE; BREAST TUMOR; FEMALE; GENETICS; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2;

EID: 84962533422     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000160     Document Type: Article

References (32)

1. World Health Organization. Fact Sheet no 297-Cancer. Geneva: World Health Organization; 2009.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the her-2/neu oncogene. Science. 1987;235:177-182.
3. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986;319:226-230.
4. Laudadio J, Quigley DI, Tubbs R, et al. Her2 testing: A review of detection methodologies and their clinical performance. Expert Rev Mol Diagn. 2007;7:53-64.
5. Ross JS, Fletcher JA, Linette GP, et al. The her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist. 2003;8:307-325.
6. Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on her-2 testing. J Clin Oncol. 2008;26:4869-4874.
7. Yeh IT, Martin MA, Robetorye RS, et al. Clinical validation of an array cgh test for her2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol. 2009;22:1169-1175.
8. Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based cgh analysis. J Pathol. 2009;219:16-24.
9. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist. 2004;9:361-377.
10. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: The her-2/neu gene and protein. Mol Cell Proteomics. 2004;3:379-398.
11. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the her-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
12. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of american pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997-4013.
13. Qin J, Jones RC, Ramakrishnan R. Studying copy number variations using a nanofluidic platform. Nucleic Acids Res. 2008;36:e116.
14. Baer M, Nilsen TW, Costigan C, et al. Structure and transcription of a human gene for h1 rna, the rna component of human rnase p. Nucleic Acids Res. 1990;18:97-103.
15. Capizzi E, Gruppioni E, Grigioni AD, et al. Real time rt-pcr approach for the evaluation of erbb2 overexpression in breast cancer archival samples: A comparative study with fish, sish, and immunohistochemistry. Diagn Mol Pathol. 2008;17:220-226.
16. Gjerdrum LM, Sorensen BS, Kjeldsen E, et al. Real-Time quantitative pcr of microdissected paraffin-embedded breast carcinoma: An alternative method for her-2/neu analysis. J Mol Diagn. 2004;6:42-51.
17. Garcia-Murillas I, Lambros M, Turner NC. Determination of her2 amplification status on tumour DNA by digital pcr. PLoS ONE. 2013;8:e83409.
18. Bustin SA, Benes V, Garson JA, et al. The miqe guidelines: minimum information for publication of quantitative real-Time pcr experiments. Clin Chem. 2009;55:611-622.
19. Pfaffl MW. A new mathematical model for relative quantification in real-Time rt-pcr. Nucleic Acids Res. 2001;29:e45.
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
21. Page K, Hava N, Ward B, et al. Detection of her2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer. 2011;104:1342-1348.
22. Tse CH, Hwang HC, Goldstein LC, et al. Determining true her2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-her2 targeted therapy. J Clin Oncol. 2011;29:4168-4174.
23. Yaziji H, Gown AM. Accuracy and precision in her2/neu testing in breast cancer: Are we there yet? Human Pathol. 2004;35:143-146.
24. Striebel JM, Bhargava R, Horbinski C, et al. The equivocally amplified her2 fish result on breast core biopsy: indications for further sampling do affect patient management. Am J Clin Pathol. 2008;129:383-390.
25. Wang J, Ramakrishnan R, Tang Z, et al. Quantifying egfr alterations in the lung cancer genome with nanofluidic digital pcr arrays. Clin Chem. 2010;56:623-632.
26. Viale G. Be precise! The need to consider the mechanisms for cep17 copy number changes in breast cancer. J Pathol. 2009;219:1-2.
27. Moelans CB, de Weger RA, van Diest PJ. Absence of chromosome 17 polysomy in breast cancer: Analysis by cep17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat. 2010;120:1-7.
28. Kulka J, Tokes AM, Kaposi-Novak P, et al. Detection of her-2/neu gene amplification in breast carcinomas using quantitative real-Time pcr-A comparison with immunohistochemical and fish results. Pathol Oncol Res. 2006;12:197-204.
29. Tse C, Brault D, Gligorov J, et al. Evaluation of the quantitative analytical methods real-Time pcr for her-2 gene quantification and elisa of serum her-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining her-2 status in breast cancer patients. Clin Chem. 2005;51: 1093-1101.
30. OMalley FP, Parkes R, Latta E, et al. Comparison of her2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol. 2001;115: 504-511.
31. Ross JS, Slodkowska EA, Symmans WF, et al. The her-2 receptor and breast cancer: Ten years of targeted anti-her-2 therapy and personalized medicine. Oncologist. 2009;14:320-368.
32. De Mattos-Arruda L, Cortes J, Santarpia L, et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nature reviews. Clin Oncol. 2013;10:377-389.